Product Description: Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Thomas S Lin, et al. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec;50(12):1958-63./[2]Matthew L. Hill DO, et al. In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines. Volume 106, Issue 11, 16 November 2005, Page 4826.
CAS Number: 267227-08-7
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Apoptosis